Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression

Area of Science:

• Molecular Biology
• Neuroscience
• Gene Therapy

Background:

• Engineered zinc-finger protein (ZFP) transcription factors can induce gene expression.
• Adenoviral vectors are a viable method for delivering therapeutic factors.
• Vascular Endothelial Growth Factor (VEGF) plays a role in neuroprotection and neurite outgrowth.

Purpose of the Study:

• To investigate the efficacy of Ad-32Ep65-Flag (Ad-p65), an engineered ZFP, in inducing VEGF-A splice variants.
• To assess the impact of Ad-p65 on motor neuron axon outgrowth in vitro.
• To evaluate Ad-p65's potential for enhancing motor neuron regeneration in vivo following nerve injury.

Main Methods:

• Transfection of primary motor neurons with Ad-p65.
• Assessment of VEGF variant expression and axon outgrowth in cultured neurons.
• In vivo study using a rat model with recurrent laryngeal nerve (RLN)-crush injury.
• Post-injury injection of Ad-p65 and evaluation of vocal fold mobility and nerve-endplate contacts.

Main Results:

• Ad-p65 transfection led to VEGF variant expression and increased axon outgrowth in primary motor neurons.
• In vivo, Ad-p65 injection post-RLN crush accelerated vocal fold recovery.
• Ad-p65 treatment increased the percentage of nerve-endplate contacts in the thyroarytenoid muscle.

Conclusions:

• Adenoviral delivery of engineered ZFP transcription factors that induce VEGF-A splice variants promotes nerve regeneration.
• ZFP transcription factor gene therapy offers a promising therapeutic strategy for nerve injury and neurodegenerative conditions.
• Targeting the full complement of VEGF-A splice variants is a key aspect of this gene therapy approach.